Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 435-440

  Yasui Furukori, Norio ^a   Kondo, Tsuyoshi ^a   Mihara, Kazuo ^a   Suzuki, Akihito ^a   Inoue, Yoshimasa ^b   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; HALOPERIDOL;

ACCOMMODATION PARALYSIS; ADULT; AGED; AKATHISIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART PALPITATION; HOSPITAL PATIENT; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPOKINESIA; HYPOSALIVATION; MALE; MEMORY DISORDER; MICTURITION DISORDER; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RIGIDITY; SCHIZOPHRENIA; SOMNOLENCE; STEADY STATE; SYMPTOMATOLOGY; TENSION; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR; VERTIGO;

ADULT; AGED; ANALYSIS OF VARIANCE; BRIEF PSYCHIATRIC RATING SCALE; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0141705754     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088902.24613.63     Document Type: Article

References (38)

1. Tsang W, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol. 1994;14:159-162.
2. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry. 1992;149:500-505.
3. Otani K, Yasui N, Kaneko S, et al. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol. 1996;11:55-57.
4. Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry. 1995;152:1038-1044.
5. LaHoste GJ, Wigal T, King BH, et al. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. Exp Clin Psychopharmacol. 2000;8:125-132.
6. Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine-a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990;10:54-57.
7. Otani K, Ishida M, Yasui N, et al. Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol. 1997;52:219-222.
8. Sramek J, Herrera J, Costa J, et al. A carbamazepine trial in chronic, treatment-refractory schizophrenia. Am J Psychiatry. 1988;145:748-750.
9. Jann MW, Fidone GS, Hernandez JM, et al. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res. 1989;28:153-159.
10. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry. 1986;143:650-651.
11. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res. 1987;22:303-310.
12. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotype. Psychopharmacology. 2002;162:50-54.
13. Otani K, Ishida M, Kaneko S, et al. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit. 1996;18:164-167.
14. Eap CB, Yasui N, Kaneko S, et al. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit. 1999;21:166-170.
15. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology. 1998;18:364-369.
16. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry. 1985;20:219-222.
17. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol. 1985;5:106-109.
18. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999;19:310-315.
19. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32:554-563.
20. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1-37.
21. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
22. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28:22-31.
23. Hikida K, Inoue Y, Miyazaki T, et al. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr. 1989;495:227-234.
24. Hikida K, Inoue Y, Kojima N, et al. Determination of pranoprofen in serum by automated column-switching high-performance liquid chromatography. Jpn J Clin Chem. 1989;18180-18183.
25. Yasui-Furukori N, Tateishi T. Carbamazepine decreases antihypertensive effect of nilvadipine. J Clin Pharmacol. 2002;42:100-103.
26. Chou JC, Czobor P, Charles O, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol. 1999;19:500-505.
27. Suzuki K, Kaneko S, Sato T. Time-dependency of serum carbamazepine concentration. Folia Psychiatr Neurol Jpn 1978;32:199-209.
28. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(suppl 2):37-44.
29. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol. 1999;19:149-154.
30. Fang J, Baker GB, Silverstone PH, et al. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol. 1997;17:227-233.
31. Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol. 1998;54:253-259.
32. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439-446.
33. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38:393-414.
34. Someya T, Shibasaki M, Noguchi T, et al. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol. 1992;12:169-174.
35. Jann MW, Lam YW, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology (Berl). 1990;101:107-111.
36. Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14:92-97.
37. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 1997;7:415-418.
38. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999;65:291-294.